A. Melnyk

Evaluation of the Revised European-American Lymphoma Classification Confirms the Clinical Relevance of Immunophenotype in 560 Cases of Aggressive Non-Hodgkin's Lymphoma

A. Melnyk, William Pugh, F. Cabannillas · Blood · 1997 · 236 citations · Full text

Medicine, Hematology, Oncology +15

Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology

Shadia I. Jalal, Heather Riggs, A. Melnyk et al. · Annals of Oncology · 2011 · 79 citations · Full text

Medicine, Oncology, Radiation Oncology +14

The PCPDTBT Family: Correlations between Chemical Structure, Polymorphism, and Device Performance

Gisela L. Schulz, Florian S. U. Fischer, Daniel Trefz et al. · Macromolecules · 2017 · 58 citations

Natural Sciences, Chemistry, Materials Science +17

Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.

Anas Younes, A H Sarris, A. Melnyk et al. · Journal of Clinical Oncology · 1995 · 40 citations

Medicine, Oncology, Pharmacology +14

Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial.

Denise A. Yardley, Milton Seiler, Isabelle Ray‐Coquard et al. · Cancer Research · 2009 · 20 citations

Medicine, Oncology, Pharmacology +17